Studies have determined that SFTPC is overexpressed in long-term surviving NSCLC patients, indicating its potential as a biomarker for lung cancer treatment (101).Furthermore, activation of the BTLA/HVEM pathway is regarded as the initiator of immune escape in lung cancer (102, 103). The gene discussed is BTLA; the disease is lung carcinoma.